Lixiana hits the mark in catheter ablation trialDaiichi Sankyo’s Lixiana was a late entrant to the novel oral anticoagulant (NOAC) category, but the Japanese drugmaker Share XLixiana hits the mark in catheter ablation trialhttps://pharmaphorum.com/news/lixiana-hits-the-mark-in-catheter-ablation-trial/
